SK1692002A3 - Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives, process for their preparation, pharmaceutical compositions comprising the same and their use - Google Patents

Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives, process for their preparation, pharmaceutical compositions comprising the same and their use Download PDF

Info

Publication number
SK1692002A3
SK1692002A3 SK169-2002A SK1692002A SK1692002A3 SK 1692002 A3 SK1692002 A3 SK 1692002A3 SK 1692002 A SK1692002 A SK 1692002A SK 1692002 A3 SK1692002 A3 SK 1692002A3
Authority
SK
Slovakia
Prior art keywords
formula
trione
substituted pyrrolidine
medicament
treatment
Prior art date
Application number
SK169-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Michael Przewosny
Hans-Dietrich Stachel
Hermann Poschenrieder
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of SK1692002A3 publication Critical patent/SK1692002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
SK169-2002A 1999-08-06 2000-07-25 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives, process for their preparation, pharmaceutical compositions comprising the same and their use SK1692002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19936521A DE19936521A1 (de) 1999-08-06 1999-08-06 Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
PCT/EP2000/007101 WO2001010831A1 (de) 1999-08-06 2000-07-25 Substituierte pyrrolidin-2,3,4-trion-3-oxim-derivate wirksam als nmda-rezeptor antagonistem

Publications (1)

Publication Number Publication Date
SK1692002A3 true SK1692002A3 (en) 2002-07-02

Family

ID=7917036

Family Applications (1)

Application Number Title Priority Date Filing Date
SK169-2002A SK1692002A3 (en) 1999-08-06 2000-07-25 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives, process for their preparation, pharmaceutical compositions comprising the same and their use

Country Status (25)

Country Link
US (1) US6716872B2 (no)
EP (1) EP1200400B1 (no)
JP (1) JP2003506436A (no)
KR (1) KR20020025215A (no)
CN (1) CN1378531A (no)
AR (1) AR030678A1 (no)
AT (1) ATE277901T1 (no)
AU (1) AU779187B2 (no)
BR (1) BR0013313A (no)
CA (1) CA2380973A1 (no)
CO (1) CO5190692A1 (no)
DE (2) DE19936521A1 (no)
ES (1) ES2226876T3 (no)
HK (1) HK1046404A1 (no)
HU (1) HUP0202433A3 (no)
IL (1) IL147978A0 (no)
MX (1) MXPA02001215A (no)
NO (1) NO20020578L (no)
NZ (1) NZ516905A (no)
PE (1) PE20010381A1 (no)
PL (1) PL353875A1 (no)
PT (1) PT1200400E (no)
SK (1) SK1692002A3 (no)
WO (1) WO2001010831A1 (no)
ZA (1) ZA200201789B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE349888T1 (de) * 2002-02-13 2007-01-15 Univ Tokyo Agriculture & Technology Tlo Co Ltd Automatisches tierbewegungsbeobachtungsverfahren und vorrichtung dafür sowie bewegungsquantisierungsvorrichtung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832790A (en) * 1954-09-28 1958-04-29 Du Pont 4-negative functionally substituted 2, 3, 5-trichalcogenpyrrolidines, their salts, and methods for preparing them
DE4317651A1 (de) * 1993-05-27 1994-12-01 Hoechst Ag Substituierte Bernsteinsäureimide
GB9418443D0 (en) * 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel

Also Published As

Publication number Publication date
ES2226876T3 (es) 2005-04-01
EP1200400A1 (de) 2002-05-02
NO20020578L (no) 2002-03-25
MXPA02001215A (es) 2002-07-02
BR0013313A (pt) 2002-04-16
DE19936521A1 (de) 2001-02-15
PL353875A1 (en) 2003-12-01
CA2380973A1 (en) 2001-02-15
IL147978A0 (en) 2002-09-12
NO20020578D0 (no) 2002-02-05
JP2003506436A (ja) 2003-02-18
HUP0202433A2 (hu) 2002-12-28
AU779187B2 (en) 2005-01-13
HUP0202433A3 (en) 2003-06-30
NZ516905A (en) 2004-07-30
ZA200201789B (en) 2003-06-25
DE50008020D1 (de) 2004-11-04
WO2001010831A1 (de) 2001-02-15
ATE277901T1 (de) 2004-10-15
AR030678A1 (es) 2003-09-03
KR20020025215A (ko) 2002-04-03
PE20010381A1 (es) 2001-05-05
CN1378531A (zh) 2002-11-06
US6716872B2 (en) 2004-04-06
CO5190692A1 (es) 2002-08-29
PT1200400E (pt) 2005-02-28
HK1046404A1 (zh) 2003-01-10
US20030027852A1 (en) 2003-02-06
AU5986800A (en) 2001-03-05
EP1200400B1 (de) 2004-09-29

Similar Documents

Publication Publication Date Title
US6642267B2 (en) Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
CZ20032696A3 (cs) Thiohydantoiny a jejich použití při léčení cukrovky
NZ539390A (en) Azaindole derivatives as inhibitors of p38 kinase
SK1692002A3 (en) Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives, process for their preparation, pharmaceutical compositions comprising the same and their use
KR101133959B1 (ko) 면역조절 헤테로고리 화합물
JP6906449B2 (ja) 複素環スルホンアミド誘導体及びそれを含有する医薬
MX2015002357A (es) Pirrol carboxamidas fluorometil sustituidas.
JP2024501641A (ja) 置換大環状化合物及び関連する治療方法
EA015175B1 (ru) Соединения, проявляющие активность в отношении рецептора св
MX2008013478A (es) Compuestos biciclicos de tetrahidropirrol.
JP2012532858A (ja) 環状トリアゾナトリウムチャネル遮断薬
RU2576037C1 (ru) Замещенные 4-{ [4-(3,3-диоксидо-1,3-бензоксатиол-6-ил)арилокси]метил} пиперидины как агонисты рецепторов gpr119, фармацевтическая композиция, способы их получения и применения
DE60107852T2 (de) Thienopyrrolidinone
EP1751101B1 (de) Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
EP3945091B1 (en) Novel vdac1 inhibitors
US20040224969A1 (en) Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds
HU211085B (hu) Eljárás spiro(píperidin-4,1’[1 H]piridio[3,4-b]indol)-származékok és az azokat tartalmazó gyógyszerkészítmények előállítására